Statins as antiarrhythmics: A systematic review part I: Effects on risk of atrial fibrillation

Clinical Cardiology

Volumn 32, Issue 10, 2009, Pages 544-548

  Abuissa, Hussam ^a   O'Keefe, James H ^a,b   Bybee, Kevin A ^a,b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLECAINIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; PROPAFENONE; SOTALOL;

BYPASS SURGERY; CARDIOVASCULAR RISK; CARDIOVERSION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; ELECTROCARDIOGRAM; ESOPHAGUS RESECTION; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART SURGERY; HUMAN; HYPERLIPIDEMIA; INCIDENCE; LUNG RESECTION; OBSERVATIONAL STUDY; POSTOPERATIVE PERIOD; PREDICTION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 70849086739     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20669     Document Type: Review

References (35)

1. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-1009.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22. (Pubitemid 34756487)
3. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98(9):839-844.
4. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15(2):247-251.
5. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997;95(5):1126-1131. (Pubitemid 27097821)
6. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol. 2003;92(12):1379-1383. (Pubitemid 37532555)
7. Marin F, Pascual DA, Roldan V, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol. 2006;97(1):55-60. (Pubitemid 41828123)
8. Dotani MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol. 2000;86(10):1128-1130, A1126.
9. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006;114(14):1455-1461. (Pubitemid 44526999)
10. Amar D, Zhang H, Heerdt PM, Park B, Fleisher M, Thaler HT. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest. 2005;128(5):3421-3427. (Pubitemid 41698673)
11. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol. 2003;92(11):1343-1345. (Pubitemid 37431149)
12. Tveit A, Grundtvig M, Gundersen T, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2004;93(6):780-782. (Pubitemid 38338579)
13. Ozaydin M, Varol E, Aslan SM, et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2006;97(10):1490-1493.
14. Hanna IR, Heeke B, Bush H, et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm. 2006;3(8):881-886. (Pubitemid 44103516)
15. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279(20):1643-1650.
16. Aranki SF, Shaw DP, Adams DH, et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation. 1996;94(3):390-397. (Pubitemid 26266124)
17. Atrial fibrillation: current understandings and research imperatives. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation. J Am Coll Cardiol. 1993;22(7):1830-1834.
18. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840-844. (Pubitemid 24076851)
19. Cha YM, Redfield MM, Shen WK, Gersh BJ. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation. 2004;109(23):2839-2843.
20. Ehrlich JR, Nattel S, Hohnloser SH. Atrial fibrillation and congestive heart failure: specific considerations at the intersection of two common and important cardiac disease sets. J Cardiovasc Electrophysiol. 2002;13(4):399-405. (Pubitemid 34407608)
21. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042-1046. (Pubitemid 39319000)
22. Amar D. Perioperative atrial tachyarrhythmias. Anesthesiology. 2002;97(6):1618-1623.
23. Amar D, Zhang H, Leung DH, Roistacher N, Kadish AH. Older age is the strongest predictor of postoperative atrial fibrillation. Anesthesiology. 2002;96(2):352-356. (Pubitemid 34121745)
24. Polanczyk CA, Goldman L, Marcantonio ER, Orav EJ, Lee TH. Supraventricular arrhythmia in patients having noncardiac surgery: clinical correlates and effect on length of stay. Ann Intern Med. 1998;129(4):279-285. (Pubitemid 28394572)
25. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001;104(2):174-180. (Pubitemid 32655834)
26. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108(10):1429-1437. (Pubitemid 33091980)
27. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97(12):1129-1135. (Pubitemid 28152885)
28. Li W AT, McTaggart F, Tsao P. Rosuvastatin inhibits monocyte/endothelial interactionsin ApoE (-/-) mice. Int J Clin Pract. 2002;24(Suppl):5.
29. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta. 1993;1165(3):335-338.
30. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol. 2004;43(11):2075-2082. (Pubitemid 38686805)
31. Tziakas DN, Chalikias GK, Stakos DA, et al. Effect of statins on collagen type I degradation in patients with coronary artery disease and atrial fibrillation. Am J Cardiol. 2008;101(2):199-202.
32. Wazni O, Martin DO, Marrouche NF, et al. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart. 2005;91(10):1303-1305. (Pubitemid 41360947)
33. Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation. 2004;109(3):363-368. (Pubitemid 38133905)
34. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45(11):1832-1839. (Pubitemid 40789940)
35. Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation. 2004;110(4):368-373. (Pubitemid 38993844)